Apple Drops Plans for iPhone Hardware Subscription Service
Apple is no longer planning to launch a hardware subscription service that would let customers “subscribe” to get a new iPhone each year,…
Related Articles
Helping Dual-Eligible Individuals Navigate Medicare and Medicaid
This Viewpoint discusses helping dual-eligible beneficiaries navigate Medicare and Medicaid coverage options.
Online Event
Image credit: Claire Agosti/SayoStudio; Concept: Ania Hupalowska If you’ve already registered, please click here to log in to the webcast. Sarah Teichmann and Aviv Regev,…
Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Multiple sclerosis leads to smoldering inflammation in the central nervous system upheld by proliferating immune cells, including B cells; however, current therapies remain insufficient to…
After decades of talk, Seagate seems ready to actually drop the HAMR hard drives
At least one gigantic cloud provider has signed off on the drives’ viability.
Vertex’s non-opioid drug meets main goal in mid-stage nerve pain trial
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug in a mid-stage study helped reduce pain tied to a condition caused by a pinched nerve…
Transoral Robotic Surgery to Treat Head and Neck Cancer
A recent podcast episode covers how a new single-port system is well-suited for oropharyngeal cancer treatment.
Fueled by social media, muscle dysmorphia in boys and men is on the rise
Experts say muscle dysmorphia, an unhealthy obsession with muscularity, is a medical consequence of shifting expectations for ideal masculine bodies.
WHO’s Investment Round: Voices of support
Testimonials from leaders committing to and raising their voices of support for a fully funded WHO. Investment in WHO yields healthy results, it is a…
Use, Spending, and Prices of Adalimumab Following Biosimilar Competition
This cross-sectional study examines the use, spending, and prices of adalimumab biosimilars in the first year of market competition in the US.
